23 Jul Sigilon Therapeutics

Posted at 15:35h in by Jancee Curl

Martha Rook, Ph.D., Chief Technical Operations Officer

Oct. 13 | 2:30pm | AVROBIO Ballroom

Cambridge, MA

(NASDAQ: SGTX)

In-person Presentation

Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes, or factors needed by patients living with chronic diseases such as hemophilia, lysosomal diseases, and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis.

www.sigilon.com

About the Event

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 100+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 1,200 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 3,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

Dates & Location

October 11-13, 2022
Carlsbad, CA

Program Organizer

By using this website you agree to accept our Privacy Policy and Terms & Conditions